A detailed history of Graham Capital Management, L.P. transactions in Ventyx Biosciences, Inc. stock. As of the latest transaction made, Graham Capital Management, L.P. holds 44,372 shares of VTYX stock, worth $116,698. This represents 0.0% of its overall portfolio holdings.

Number of Shares
44,372
Previous 217,646 79.61%
Holding current value
$116,698
Previous $250,000 62.4%
% of portfolio
0.0%
Previous 0.01%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Aug 14, 2025

SELL
$0.84 - $2.65 $145,550 - $459,176
-173,274 Reduced 79.61%
44,372 $94,000
Q1 2025

May 15, 2025

BUY
$1.15 - $2.52 $250,292 - $548,467
217,646 New
217,646 $250,000
Q3 2024

Nov 14, 2024

SELL
$1.85 - $3.2 $314,450 - $543,913
-169,973 Reduced 76.94%
50,956 $111,000
Q2 2024

Aug 14, 2024

BUY
$2.31 - $5.59 $510,345 - $1.23 Million
220,929 New
220,929 $510,000
Q4 2023

Feb 14, 2024

BUY
$2.08 - $31.18 $963,283 - $14.4 Million
463,117 New
463,117 $1.14 Million

Others Institutions Holding VTYX

About Ventyx Biosciences, Inc.


  • Ticker VTYX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,527,200
  • Market Cap $149M
  • Description
  • Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis...
More about VTYX
Track This Portfolio

Track Graham Capital Management, L.P. Portfolio

Follow Graham Capital Management, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Graham Capital Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Graham Capital Management, L.P. with notifications on news.